ABOUT
HYFACOL

HyFaCol is a Collagen Manufacturing Platform which significantly improves the production and quality of medical grade collagen, a $6bn a year and growing industry.

Developed over ten years at the University of Leeds by a team of world recognised academic and industry experts the HyFaCol platform will be at the forefront of the development of quality products for the advanced wound care and Guided Bone Regeneration (GBR) market.

£3m

of institutional and grant funding has already been invested in the platform.

of institutional and grant funding has already been invested in the platform.

HYFACOL is now ready to begin the human clinical trial process ahead of entering and disrupting the exponentially growing multi-billion dollar advanced wound care and guided bone regeneration markets.

By bringing significant improvements in technology, HYFACOL not only plans to disrupt the medical grade collagen based products markets but also the non-collagen based wound dressing and GBR markets.

IP is secure with patents already granted in key markets of the EU and US.

IP is secure with patents already granted in key markets of the EU and US.